Blue-Blocking Glasses + Time-Restricted Eating for Bipolar Mania
(CIS Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are taking hypoglycemia-inducing medications, you cannot participate in the trial.
What data supports the effectiveness of the treatment Blue-Blocking Glasses + Time-Restricted Eating for Bipolar Mania?
Research suggests that irregular eating patterns are linked to mood instability in people with bipolar disorder, and time-restricted eating may help stabilize these patterns. Additionally, blue-blocking glasses can improve sleep quality, which is often disrupted in bipolar disorder, potentially helping to manage mood symptoms.12345
Is time-restricted eating safe for humans?
Time-restricted eating (TRE) and time-restricted feeding (TRF) have been studied in adults with obesity and found to be generally safe, with no significant changes in adverse events or disordered eating patterns over 12 weeks. However, intermittent fasting (IF) has been associated with eating disorder symptoms in some individuals, suggesting that while TRE/TRF can be safe, IF may not be suitable for everyone.678910
How does the treatment of blue-blocking glasses and time-restricted eating for bipolar mania differ from other treatments?
This treatment is unique because it combines blue-blocking glasses, which may help regulate sleep patterns by reducing exposure to blue light, with time-restricted eating, a form of intermittent fasting that confines eating to specific hours. Unlike traditional medications for bipolar mania, this approach focuses on lifestyle changes that may influence mental health through improved sleep and metabolic regulation.6891112
What is the purpose of this trial?
The sleep-wake cycle is severely disrupted during an episode of mania. Often mania is treated with medications that can come with significant side effects. Years of patient and family engagement with this population have revealed great interest in therapies targeting the sleep-wake cycle. However, there is still a lack of studies to support using these treatments for mania. Patient partners are especially interested in two specific therapies for mania, blue-blocking glasses and time-restricted eating, because of their perceived feasibility and safety. This pilot study will formally investigate the feasibility and effectiveness of these therapies for participants with mania, an understudied population that faces many difficulties even after recovery. The pilot study will collect interviews to identify barriers and ways to better support patients with mania using the therapies. The study will also investigate how well these therapies can treat manic symptoms and restore sleep-wake cycles by tracking symptom rating scales and measuring activity levels. Results from this pilot will be used to direct a larger study that will use a state-of-the art design to test the effectiveness of both therapies alone and in combination.
Research Team
Jess G Fiedorowicz, MD, PhD
Principal Investigator
Ottawa Hospital Research Institute
Eligibility Criteria
This trial is for individuals experiencing mania as part of bipolar disorder. Participants should be interested in non-medication therapies and willing to try special glasses or change their eating patterns. Details on specific inclusion or exclusion criteria are not provided, but typically these would outline who can safely participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive blue-blocking glasses, time-restricted eating, or both as interventions for mania
Follow-up
Participants are monitored for safety and effectiveness after treatment
Qualitative Interviews
Interviews conducted to assess feasibility and identify barriers to treatment
Treatment Details
Interventions
- Blue-blocking glasses
- Time-restricted eating
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Hospital Research Institute
Lead Sponsor